Search by drug, manufacturer, or indication

Displaying 1151 - 1160 of 1165

Tykerb & Letrozole (lapatinib)

Status:

Negotiations were not pursued

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer

Last updated August 9, 2013

Xalkori (crizotinib)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Non-Squamous Non-Small Cell Lung Cancer

Last updated August 8, 2013

Effient (prasugrel)

Status:

Concluded with an LOI

Manufacturer:

Eli Lilly Canada Inc.

Indication:

Acute Coronary Syndrome

Last updated August 7, 2013

Seebri (glycopyrronium bromide)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated July 29, 2013

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)

Status:

Concluded with an LOI

Manufacturer:

Gilead Sciences Canada Inc.

Indication:

HIV-1 Infection

Last updated July 11, 2013

Halaven (eribulin)

Status:

Concluded with an LOI

Manufacturer:

Eisai Limited

Indication:

Metastatic Breast Cancer

Last updated July 2, 2013

Byetta (exenatide)

Status:

Concluded without agreement

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated June 13, 2013

Tysabri (natalizumab)

Status:

Concluded with an LOI

Manufacturer:

Biogen Canada Inc.

Indication:

Multiple Sclerosis, Relapsing-Remitting

Last updated December 1, 2013

Treanda (bendamustine hydrochloride)

Status:

Concluded with an LOI

Manufacturer:

Lundbeck Canada Inc.

Indication:

Non-Hodgkin's Lymphoma

Last updated April 25, 2013

Onbrez (indacaterol)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Chronic Obstructive Pulmonary Disease (COPD)

Last updated April 12, 2013